Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
You must be a Standard 1 Year member to access this content.
Cooley advised SystImmune on the transaction. SystImmune announced its exclusive license and collaboration agreement with Bristol Myers Squibb (NYSE: BMY) for SystImmune’s BL-B01D1. Under the terms of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Cooley represented Turnstone, and Latham & Watkins represented the underwriters in the IPO. Turnstone Biologics Corp. (Nasdaq: TSBX) announced the pricing of its upsized initial public...
You must be a Standard 1 Year member to access this content.
Cooley advised Seven and Eight Biopharmaceuticals on the deal. Seven and Eight Biopharmaceuticals Inc. announced that it has signed an exclusive licensing agreement with Eikon Therapeutics....
You must be a Standard 1 Year member to access this content.
Cooley advised Impact Therapeutics on the deal. Impact Therapeutics and Eikon Therapeutics announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors...
You must be a Standard 1 Year member to access this content.
Cooley advised Zai Lab on the deal. Zai Lab, a research-based commercial-stage biopharmaceutical company, announced its strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics, as...
You must be a Standard 1 Year member to access this content.
Cooley advised Zion Pharma Limited on the deal. Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, announced the acquisition of its...
You must be a Standard 1 Year member to access this content.
Gibson Dunn acted as legal advisor to RTW, and Cooley acted as legal advisor to Milestone. Milestone Pharmaceuticals Inc. announced that it has entered into a...
You must be a Standard 1 Year member to access this content.
Goodwin Procter and Debevoise & Plimpton advised Carlyle on the deal, while Cooley and Gilbert+Tobin advised Opthea. Global investment firm Carlyle and its life sciences franchise...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Lulu’s in the offering while Cooley advised the underwriters. Lulu’s Fashion Lounge Holdings, Inc., a customer driven, digitally native women’s fashion brand, has...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Engine Biosciences on the deal. Engine Biosciences, a company deciphering complex biology to create medicines, announced its $43 million Series A financing round. Polaris...
You must be a Standard 1 Year member to access this content.
